Meeting
2016 ASCO Annual Meeting
Extension of overall survival in patients with metastatic renal cell carcinoma who received HD IL-2 followed by targeted therapy and/or immune checkpoint blockade from the PROCLAIM registry.
Authors
Joseph Clark
Loyola University Medical Center, Maywood, IL
Joseph Clark , David F. McDermott , Janice P. Dutcher , Michael K.K. Wong , Howard Kaufman , Gregory A. Daniels , Michael Morse , Jessica C. Perritt , Hong Hua , Tharaknath Rao
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT01415167
Citation
J Clin Oncol 34, 2016 (suppl; abstr 4548)
DOI
10.1200/JCO.2016.34.15_suppl.4548
Abstract #
4548
Poster Bd #
170
Abstract Disclosures
Similar Posters
Poster
2019 Genitourinary Cancers Symposium
Impact of body mass index (BMI) on treatment outcomes to immune checkpoint blockade (ICB) in metastatic renal cell carcinoma (mRCC).
First Author: Aly-Khan A. Lalani
Poster
2016 Genitourinary Cancers Symposium
Durability of responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2 (HD IL-2).
First Author: Joseph Clark
Poster
2020 Genitourinary Cancers Symposium
Expectations for overall survival in mRCC patients who were selected for upfront cytoreductive nephrectomy in the targeted therapy era.
First Author: E. Jason Abel
Poster
2015 ASCO Annual Meeting
Extension of overall survival (OS) beyond objective responses (OR) in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with high dose interleukin-2 (HD IL-2).
First Author: David D. Stenehjem